You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluocinolone Acetonide
Accession NumberDB00591  (APRD00977)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionA glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). It is also being investigated by Sivida and Alimera, under the brand name Medidur, as a sustained release intraocular implant for the treatment of diabetic macular edema.
Structure
Thumb
Synonyms
6alpha-fluorotriamcinolone acetonide
6alpha,9alpha-difluoro-16alpha-hydroxyprednisolone 16,17-acetonide
6α-fluorotriamcinolone acetonide
6α,9α-difluoro-16α-hydroxyprednisolone 16,17-acetonide
acétonide de fluocinolone
acetónido de fluocinolona
fluocinolon acetonid
fluocinolone 16,17-acetonide
fluocinoloni acetonidum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CapexKitGalderma Laboratories, L.P.1984-10-12Not applicableUs
CapexShampoo0.01 %TopicalGalderma Canada Inc2001-02-022014-07-15Canada
Derma Smoothe/fs Liq 0.01%Liquid0.01 %TopicalHill Dermaceuticals Inc1991-12-31Not applicableCanada
Derma-smoothe/fsOil.11 mg/mLTopicalPhysicians Total Care, Inc.2009-09-03Not applicableUs
Derma-smoothe/fsOil.11 mg/mLTopicalHill Dermaceuticals, Inc.1995-02-162015-12-29Us
Derma-smoothe/fsOil.11 mg/mLTopicalRoyal Pharmaceuticals1995-02-16Not applicableUs
Derma-smoothe/fsOil.11 mg/mLTopicalHill Dermaceuticals, Inc.1988-02-032015-12-29Us
Derma-smoothe/fsOil.11 mg/mLTopicalRoyal Pharmaceuticals1995-02-16Not applicableUs
DermoticOil.11 mg/mLAuricular (otic)Hill Dermaceuticals, Inc.2005-11-092015-12-29Us
DermoticOil.11 mg/mLAuricular (otic)Royal Pharmaceuticals2005-11-09Not applicableUs
Dermotic Oil Ear DropsSolution0.01 %Auricular (otic)Hill Dermaceuticals Inc2008-01-09Not applicableCanada
Fluocinolone AcetonideSolution.1 mg/mLTopicalTeligent Pharma, Inc.2012-11-27Not applicableUs
Fluocinolone AcetonideOil.11 mg/mLTopicalSeton Pharmaceuticals2013-08-20Not applicableUs
Fluocinolone AcetonideOintment.25 mg/gTopicalIGI Labs, Inc.2012-12-27Not applicableUs
Fluocinolone AcetonideOil.11 mg/mLTopicalSeton Pharmaceuticals2013-08-01Not applicableUs
Fluocinolone AcetonideCream.25 mg/gTopicalIGI Labs, Inc.2012-12-28Not applicableUs
Fluocinolone AcetonideCream.1 mg/gTopicalIGI Labs, Inc.2014-05-15Not applicableUs
Fluocinolone Acetonide 0.01%Oil.11 mg/mLAuricular (otic)Seton Pharmaceuticals2013-08-01Not applicableUs
Fluoderm Crm 0.01%Cream.01 %TopicalTaro Pharmaceuticals Inc1979-12-31Not applicableCanada
Fluoderm Crm 0.025%Cream.025 %TopicalTaro Pharmaceuticals Inc1979-12-31Not applicableCanada
Fluoderm Ont 0.01%Ointment.1 mgTopicalTaro Pharmaceuticals Inc1979-12-312001-08-21Canada
Fluoderm Ont 0.025%Ointment0.25 mgTopicalTaro Pharmaceuticals Inc1979-12-31Not applicableCanada
FS Shampoo-0.01%Shampoo.01 %TopicalHill Dermaceuticals Inc1994-12-312000-11-02Canada
IluvienImplant.19 mg/1IntravitrealAlimera Sciences, Inc.2014-10-15Not applicableUs
RetisertImplant.59 mg/1IntravitrealBausch & Lomb Incorporated2005-04-08Not applicableUs
RetisertImplant0.59 mgIntravitrealBausch & Lomb Inc2012-09-13Not applicableCanada
SynalarOintment.25 mg/gTopicalMedimetriks Pharmaceuticals, Inc.2012-09-27Not applicableUs
SynalarKitTopicalMedimetriks Pharmaceuticals, Inc.2012-12-15Not applicableUs
SynalarCream.25 mg/gTopicalMedimetriks Pharmaceuticals, Inc.2012-09-27Not applicableUs
SynalarSolution.1 mg/mLTopicalMedimetriks Pharmaceuticals, Inc.2012-05-31Not applicableUs
SynalarKitTopicalMedimetriks Pharmaceuticals, Inc.2012-12-15Not applicableUs
Synalar Cream 0.025%Cream0.025 %TopicalMedicis Canada Ltd.1970-12-311998-09-25Canada
Synalar Cream Mild 0.01%Cream0.01 %TopicalMedicis Canada Ltd.1967-12-311998-09-25Canada
Synalar Ointment 0.025%Ointment0.025 %TopicalValeant Canada Lp/valeant Canada s.e.c.1996-12-31Not applicableCanada
Synalar Ointment Mild 0.01%Ointment0.01 %TopicalMedicis Canada Ltd.1968-12-311998-09-25Canada
Synalar Ont Regular 0.025%Ointment.025 %TopicalSyntex Inc.1963-12-311996-09-30Canada
Synalar Solution 0.01%Solution0.01 %TopicalValeant Canada Lp/valeant Canada s.e.c.1996-12-31Not applicableCanada
Synalar TsKitMedimetriks Pharmaceuticals, Inc.2012-08-15Not applicableUs
Synamol Mild 0.01% CreamCream0.01 %TopicalMedicis Canada Ltd.1978-12-311998-09-25Canada
Synamol Regular 0.025% CreamCream0.025 %TopicalMedicis Canada Ltd.1978-12-311998-09-25Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fluocinolone AcetonideOil.11 mg/118.28mLTopicalAv Kare, Inc.2013-12-17Not applicableUs
Fluocinolone AcetonideOil.11 mg/118.28mLTopicalTaro Pharmaceuticals U.S.A., Inc.2016-05-19Not applicableUs
Fluocinolone AcetonideCream.1 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1982-12-16Not applicableUs
Fluocinolone AcetonideOil.11 mg/20mLAuricular (otic)Amneal Pharmaceuticals, LLC2015-09-22Not applicableUs
Fluocinolone AcetonideOintment.25 mg/gTopicalG&W Laboratories, Inc.1988-07-26Not applicableUs
Fluocinolone AcetonideCream.1 mg/gTopicalA S Medication Solutions Llc1982-12-16Not applicableUs
Fluocinolone AcetonideCream.25 mg/gTopicalG&W Laboratories, Inc.2013-12-20Not applicableUs
Fluocinolone AcetonideOil.11 mg/118.28mLTopicalAv Kare, Inc.2013-12-17Not applicableUs
Fluocinolone AcetonideOil.11 mg/118.28mLTopicalTaro Pharmaceuticals U.S.A., Inc.2016-05-19Not applicableUs
Fluocinolone AcetonideSolution.1 mg/mLTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1982-12-16Not applicableUs
Fluocinolone AcetonideOil.11 mg/118.28mLTopicalAmneal Pharmaceuticals, LLC2015-09-22Not applicableUs
Fluocinolone AcetonideSolution.1 mg/mLTopicalPhysicians Total Care, Inc.1996-04-03Not applicableUs
Fluocinolone AcetonideCream.1 mg/gTopicalSTAT Rx USA LLC1982-12-16Not applicableUs
Fluocinolone AcetonideSolution.1 mg/mLTopicalGAVIS Pharmaceuticals, LLC2015-09-02Not applicableUs
Fluocinolone AcetonideOil.11 mg/mLAuricular (otic)Versa Pharm Incorporated2016-09-13Not applicableUs
Fluocinolone AcetonideCream.25 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1982-12-16Not applicableUs
Fluocinolone AcetonideOil.11 mg/118.28mLTopicalAmneal Pharmaceuticals, LLC2015-09-22Not applicableUs
Fluocinolone AcetonideOil.11 mg/118.28mLTopicalPhysicians Total Care, Inc.2012-04-26Not applicableUs
Fluocinolone AcetonideCream.25 mg/gTopicalG&W Laboratories, Inc.1988-07-26Not applicableUs
Fluocinolone AcetonideOil.11 mg/20mLAuricular (otic)Av Kare, Inc.2013-12-18Not applicableUs
Fluocinolone AcetonideSolution.1 mg/mLTopicalG&W Laboratories, Inc.2016-09-28Not applicableUs
Fluocinolone AcetonideSolution.1 mg/mLTopicalTaro Pharmaceuticals U.S.A., Inc.2015-03-27Not applicableUs
Fluocinolone AcetonideOintment.25 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1982-12-16Not applicableUs
Fluocinolone AcetonideOil.11 mg/118.28mLTopicalPhysicians Total Care, Inc.2012-12-07Not applicableUs
Fluocinolone AcetonideCream.1 mg/gTopicalG&W Laboratories, Inc.1988-07-26Not applicableUs
Fluocinolone Acetonide OilOil.11 mg/mLTopicalRising Pharmaceuticals, Inc.2016-07-18Not applicableUs
Fluocinolone Acetonide OilOil.11 mg/mLTopicalLyne Laboratories, Inc.2016-07-01Not applicableUs
Fluocinolone Acetonide OilOil.11 mg/mLAuricular (otic)Rising Pharmaceuticals, Inc.2016-09-14Not applicableUs
Fluocinolone Acetonide OilOil.11 mg/mLAuricular (otic)Lyne Laboratories, Inc.2016-07-01Not applicableUs
Fluocinolone Acetonide OilOil.11 mg/mLTopicalRising Pharmaceuticals, Inc.2016-07-18Not applicableUs
Fluocinolone Acetonide OilOil.11 mg/mLTopicalLyne Laboratories, Inc.2016-07-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CoriphateNot Available
CortiplastolNot Available
DermalarTeva
FlucinarJelfa
FlucortNot Available
FluocetNot Available
FluonidBiolab
FluotrexNot Available
FluovitifNot Available
FlupollonMayado Seiyaku
FluzonNot Available
FutocanShinlon
JellinGrünenthal
LocafluoRecordati
LocalynNot Available
MeclodermICI
OmnidermNot Available
PercutinaNot Available
ProderminNot Available
RadiocinNot Available
SinalarNot Available
SynamolNot Available
SynandoneNot Available
SynandroneNot Available
SynemolNot Available
SynoticNot Available
SynsacNot Available
TefunoteNot Available
Brand mixtures
NameLabellerIngredients
Neo-synalarMedimetriks Pharmaceuticals
OtovelArbor Pharmaceuticals
Synalar Bi-otic SolutionMedicis Canada Ltd.
Tri-lumaGalderma Laboratories, L.P.
SaltsNot Available
Categories
UNII0CD5FD6S2M
CAS number67-73-2
WeightAverage: 452.4882
Monoisotopic: 452.201045102
Chemical FormulaC24H30F2O6
InChI KeyFEBLZLNTKCEFIT-VSXGLTOVSA-N
InChI
InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1
IUPAC Name
(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-14,17-dien-16-one
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO
Pharmacology
IndicationFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (Retisert).
Structured Indications
PharmacodynamicsNot Available
Mechanism of actionFluocinolone Acetonide is a corticosteroid that binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. Cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In another words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Like other glucocorticoid agents Fluocinolone acetonide acts as a physiological antagonist to insulin by decreasing glycogenesis (formation of glycogen). It also promotes the breakdown of lipids (lipolysis), and proteins, leading to the mobilization of extrahepatic amino acids and ketone bodies. This leads to increased circulating glucose concentrations (in the blood). There is also decreased glycogen formation in the liver.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionRapidly absorbed (15 minutes)
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Primarily hepatic, corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Route of eliminationCorticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Half life1.3-1.7 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fluocinolone Acetonide.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Fluocinolone Acetonide.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluocinolone Acetonide.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fluocinolone Acetonide.Approved
AldesleukinFluocinolone Acetonide may decrease the antineoplastic activities of Aldesleukin.Approved
ALT-110The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluocinolone Acetonide.Approved
AmiodaroneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BFluocinolone Acetonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluocinolone Acetonide.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluocinolone Acetonide.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Fluocinolone Acetonide.Approved, Investigational
AprepitantThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Fluocinolone Acetonide.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocinolone Acetonide.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluocinolone Acetonide.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluocinolone Acetonide.Approved, Investigational
BazedoxifeneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideFluocinolone Acetonide may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluocinolone Acetonide.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Fluocinolone Acetonide.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Fluocinolone Acetonide.Investigational
Bismuth SubcitrateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Boceprevir.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluocinolone Acetonide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluocinolone Acetonide.Investigational
BumetanideFluocinolone Acetonide may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluocinolone Acetonide.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluocinolone Acetonide.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluocinolone Acetonide.Experimental
CDX-110The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluocinolone Acetonide.Approved, Investigational
CeritinibFluocinolone Acetonide may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fluocinolone Acetonide.Approved, Vet Approved
ChlorothiazideFluocinolone Acetonide may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneFluocinolone Acetonide may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Fluocinolone Acetonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluocinolone Acetonide.Approved
CobicistatThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Fluocinolone Acetonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fluocinolone Acetonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluocinolone Acetonide.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluocinolone Acetonide.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Fluocinolone Acetonide.Investigational
DarunavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Fluocinolone Acetonide.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fluocinolone Acetonide.Approved, Vet Approved
DienestrolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluocinolone Acetonide.Approved
DihydrotestosteroneFluocinolone Acetonide may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluocinolone Acetonide.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluocinolone Acetonide.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Fluocinolone Acetonide.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Fluocinolone Acetonide.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluocinolone Acetonide.Approved
EstradiolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estrone.Approved
Etacrynic acidFluocinolone Acetonide may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Fluocinolone Acetonide.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluocinolone Acetonide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluocinolone Acetonide.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Fluocinolone Acetonide.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Fluocinolone Acetonide.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluocinolone Acetonide.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluocinolone Acetonide.Approved
FenthionThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fluocinolone Acetonide.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Fluocinolone Acetonide.Vet Approved
FluoxymesteroneFluocinolone Acetonide may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fluocinolone Acetonide.Approved, Investigational
FosaprepitantThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Fosphenytoin.Approved
FurosemideFluocinolone Acetonide may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Fluocinolone Acetonide.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluocinolone Acetonide.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Fluocinolone Acetonide.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocinolone Acetonide.Approved, Investigational
HydrochlorothiazideFluocinolone Acetonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideFluocinolone Acetonide may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluocinolone Acetonide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Fluocinolone Acetonide.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Fluocinolone Acetonide.Approved
IdelalisibThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Fluocinolone Acetonide.Approved
IndapamideFluocinolone Acetonide may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluocinolone Acetonide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluocinolone Acetonide.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with INGN 225.Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Fluocinolone Acetonide.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluocinolone Acetonide.Withdrawn
ItraconazoleThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluocinolone Acetonide.Experimental
KetoconazoleThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocinolone Acetonide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluocinolone Acetonide.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Fluocinolone Acetonide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluocinolone Acetonide.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluocinolone Acetonide.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluocinolone Acetonide.Approved
LumacaftorThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fluocinolone Acetonide.Approved, Investigational
MagaldrateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluocinolone Acetonide.Approved
Magnesium TrisilicateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluocinolone Acetonide.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinolone Acetonide.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluocinolone Acetonide.Approved
MefloquineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluocinolone Acetonide.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluocinolone Acetonide.Approved
MestranolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluocinolone Acetonide.Withdrawn
MethallenestrilThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideFluocinolone Acetonide may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneFluocinolone Acetonide may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneFluocinolone Acetonide may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Fluocinolone Acetonide can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Minaprine.Approved
MitotaneThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Fluocinolone Acetonide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluocinolone Acetonide.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluocinolone Acetonide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocinolone Acetonide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluocinolone Acetonide.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluocinolone Acetonide.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluocinolone Acetonide.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Fluocinolone Acetonide.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Fluocinolone Acetonide.Investigational
NefazodoneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluocinolone Acetonide.Approved
NevirapineThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluocinolone Acetonide.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluocinolone Acetonide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluocinolone Acetonide.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluocinolone Acetonide.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocinolone Acetonide.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Fluocinolone Acetonide.Vet Approved
OxandroloneFluocinolone Acetonide may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluocinolone Acetonide.Approved
OxymetholoneFluocinolone Acetonide may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluocinolone Acetonide.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fluocinolone Acetonide.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fluocinolone Acetonide.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluocinolone Acetonide.Approved, Vet Approved
PhenytoinThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluocinolone Acetonide.Approved, Investigational
PiretanideFluocinolone Acetonide may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluocinolone Acetonide.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluocinolone Acetonide.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideFluocinolone Acetonide may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluocinolone Acetonide.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Fluocinolone Acetonide.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Quinestrol.Approved
QuinethazoneFluocinolone Acetonide may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rabies vaccine.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Fluocinolone Acetonide.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocinolone Acetonide.Experimental, Investigational
RifabutinThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Rifapentine.Approved
RitonavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Fluocinolone Acetonide.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rosoxacin.Approved
S EquolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocinolone Acetonide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluocinolone Acetonide.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluocinolone Acetonide.Approved
SaquinavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluocinolone Acetonide.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Fluocinolone Acetonide.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Fluocinolone Acetonide.Investigational
St. John's WortThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololFluocinolone Acetonide may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluocinolone Acetonide.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Fluocinolone Acetonide.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluocinolone Acetonide.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Fluocinolone Acetonide.Approved
TelithromycinThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluocinolone Acetonide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Fluocinolone Acetonide.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluocinolone Acetonide.Approved
TestosteroneFluocinolone Acetonide may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluocinolone Acetonide.Approved
TiboloneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluocinolone Acetonide.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluocinolone Acetonide.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluocinolone Acetonide.Approved
TorasemideFluocinolone Acetonide may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluocinolone Acetonide.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Trichlorfon.Vet Approved
TrichlormethiazideFluocinolone Acetonide may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fluocinolone Acetonide.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluocinolone Acetonide.Investigational, Withdrawn
VoriconazoleThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinFluocinolone Acetonide may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluocinolone Acetonide.Approved
ZeranolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Fluocinolone Acetonide.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluocinolone Acetonide.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Mills, J.S. and Bowers, A.; U.S. Patent 3,014,938; December 26, 1961; assigned to Syntex SA, Mexico.

General References
  1. Goldstein DA, Godfrey DG, Hall A, Callanan DG, Jaffe GJ, Pearson PA, Usner DW, Comstock TL: Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007 Nov;125(11):1478-85. Epub 2007 Oct 8. [PubMed:17923537 ]
  2. Brumm MV, Nguyen QD: Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management. Int J Nanomedicine. 2007;2(1):55-64. [PubMed:17722513 ]
  3. Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P: Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3569-75. [PubMed:11006254 ]
External Links
ATC CodesS02BA08S01BA15S01CA10S02CA05D07BC02D07CC02D07AC04C05AA10
AHFS Codes
  • 84:06.00
PDB EntriesNot Available
FDA labelDownload (49.7 KB)
MSDSDownload (75.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9865
Blood Brain Barrier+0.9683
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.7912
P-glycoprotein inhibitor INon-inhibitor0.5674
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8304
CYP450 2C9 substrateNon-substrate0.8679
CYP450 2D6 substrateNon-substrate0.8856
CYP450 3A4 substrateSubstrate0.6964
CYP450 1A2 substrateNon-inhibitor0.9327
CYP450 2C9 inhibitorNon-inhibitor0.9394
CYP450 2D6 inhibitorNon-inhibitor0.9559
CYP450 2C19 inhibitorNon-inhibitor0.9311
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8806
Ames testNon AMES toxic0.7682
CarcinogenicityNon-carcinogens0.9174
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7033 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9838
hERG inhibition (predictor II)Non-inhibitor0.671
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alpharma us pharmaceuticals division
  • E fougera div altana inc
  • G and w laboratories inc
  • Perrigo new york inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Taro pharmaceuticals inc
  • Taro pharmaceuticals usa inc
  • Usl pharma inc
  • Allergan herbert div allergan inc
  • Savage laboratories inc div altana inc
  • Medicis pharmaceutical corp
  • Bausch and lomb inc
  • Hill dermaceuticals inc
  • Galderma laboratories lp
  • Bausch and lomb pharmaceuticals inc
  • Morton grove pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Kit
ShampooTopical0.01 %
LiquidTopical0.01 %
SolutionAuricular (otic)0.01 %
CreamTopical.1 mg/g
CreamTopical.25 mg/g
OilAuricular (otic).11 mg/20mL
OilTopical.11 mg/118.28mL
OilTopical.11 mg/mL
OintmentTopical.25 mg/g
SolutionTopical.1 mg/mL
OilAuricular (otic).11 mg/mL
CreamTopical.01 %
CreamTopical.025 %
OintmentTopical.1 mg
OintmentTopical0.25 mg
ShampooTopical.01 %
ImplantIntravitreal.19 mg/1
Kit
For solutionAuricular (otic)
ImplantIntravitreal.59 mg/1
ImplantIntravitreal0.59 mg
KitTopical
SolutionAuricular (otic)
CreamTopical0.025 %
OintmentTopical0.025 %
OintmentTopical0.01 %
OintmentTopical.025 %
SolutionTopical0.01 %
CreamTopical0.01 %
CreamTopical
Prices
Unit descriptionCostUnit
Retisert implant21900.0USD each
Synalar 0.01% Solution 60ml Bottle108.72USD bottle
Synalar 0.025% Cream 60 gm Tube103.1USD tube
Synalar 0.025% Ointment 60 gm Tube103.1USD tube
Fluocinolone Acetonide 0.01% Cream 15 gm Tube76.61USD tube
Fluocinolone Acetonide 0.01% Cream 60 gm Tube73.5USD tube
Fluocinolone Acetonide 0.025% Cream 15 gm Tube46.1USD tube
Fluocinolone Acetonide 0.025% Cream 60 gm Tube38.99USD tube
Fluocinolone Acetonide 0.025% Ointment 60 gm Tube38.99USD tube
Fluocinolone acetonide powder35.28USD g
Fluocinolone Acetonide 0.025% Ointment 15 gm Tube33.47USD tube
Fluocinolone Acetonide 0.01% Solution 60ml Bottle20.45USD bottle
Dermotic oil 0.01% ear drops1.75USD ml
Derma-smoothe-fs scalp oil0.35USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6217895 No1999-03-222019-03-22Us
US6375972 No2000-04-262020-04-26Us
US6548078 No1999-03-222019-03-22Us
US7915243 No2006-03-222026-03-22Us
US7939516 No2005-05-042025-05-04Us
US8247395 No2002-10-222022-10-22Us
US8252307 No1999-06-272019-06-27Us
US8653053 No2002-10-252022-10-25Us
US8871241 No2007-08-122027-08-12Us
US8932610 No2010-03-242030-03-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point266-268Mills, J.S. and Bowers, A.; U.S. Patent 3,014,938; December 26, 1961; assigned to Syntex SA, Mexico.
logP2.48HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0547 mg/mLALOGPS
logP2.47ALOGPS
logP1.6ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.35ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity111.41 m3·mol-1ChemAxon
Polarizability44.97 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 6-halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Meta-dioxolane
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Nehme A, Lobenhofer EK, Stamer WD, Edelman JL: Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics. 2009 Sep 10;2:58. doi: 10.1186/1755-8794-2-58. [PubMed:19744340 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Phospholipase a2 activity
Specific Function:
Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.
Gene Name:
PLA2G4A
Uniprot ID:
P47712
Molecular Weight:
85238.2 Da
References
  1. Norris JF, Ilderton E, Yardley HJ, Summerly R, Forster S: Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203. [PubMed:6743552 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2016 03:45